Table 3 Progression-free survival (PFS) according to different subgroups.

Subgroup	n	Median (95% CI) PFS, months	p value (log-rank)
Age, years
75–79	63	22.7 (15–NR)	0.66
≥ 80	69	19.4 (10.4–22.9)	0.66
Sex
Male	38	19.6 (13.3–NR)	0.89
Female	94	19.4 (15.8–NR)	0.89
Smoking history
Yes	40	16.1 (9.5–NR)	0.61
No	92	21.2 (15.9–NR)	0.61
Clinical stage
III or IV	98	16.3 (13.3–22.6)	0.139
Recurrence^a	34	22.9 (16.6–NR)	0.139
Performance status
0–1	113	21.2 (15.8–NR)	0.040
≥ 2	19	16.1 (4.1–17.7)	0.040
Brain metastasis
Present	27	17.3 (11.8–21.2)	0.46
Absent	105	22.6 (15.8–NR)	0.46
EGFR mutation^b
Exon 19 deletion	44	22.6 (15.8–NR)	0.69
L858R	80	16.6 (12.2–NR)	0.69
CCI
0–1	98	19.6 (15.9–23.9)	0.87
≥ 2	34	17.3 (10.5–NR)	0.87
BSA^c
< 1.5	88	19.4 (13.3–23.9)	0.50
≥ 1.5	42	19.6 (15–NR)

BSA body surface area, CCI Charlson comorbidity index, CI confidence interval, EGFR epidermal growth factor, receptor, NR not reached.
^aRecurrence after complete resection or curative-intent (chemo) radiotherapy.
^bPatients could have more than one type of mutation. A patient who has compound mutation of exon 19 deletion and L858R was excluded from this subgroup analysis.
^cPatients whose data on height or weight were not available were excluded from this subgroup analysis.

Quick links

Search